Showing posts with label Week ahead. Show all posts
Showing posts with label Week ahead. Show all posts

Sunday, August 20, 2017

Weighing The Week Ahead: Is A Market-Friendly Policy Agenda Now In Peril?

Image result for businessman using scales and weights

Includes: CRFDDMDIADOGDXDEEHEPSEQLFEXFWDDHUS

Summary

Economic news remains positive with very low recession odds.
Markets found a new reason for nervousness -- changes within the Trump Administration.
In a quiet week for data, participants will look ahead to Chair Yellen's Friday speech at Jackson Hole.
Expect continuing speculation about the prospects for market-friendly policies.
Bipartisanship is needed to advance key policies.
Once again, the expected quiet summer week was instead filled with action. With analysts of all stripes analyzing every aspect of the changes in the Trump Administration, the financial punditry will do the same. Ignoring the politics and personalities, we are still left with a question that is important to investors:
Is a Market-Friendly Policy Agenda Now in Peril?

Last Week Recap

My notion that last week would be all about Korea and a possible correction was only half right. The Charlottesville events, the aftermath, and the President’s reactions took center stage. The turmoil once again offered a reason to sell. Once again this occurred despite a good week for economic data.

The Story in One Chart

I always start my personal review of the week by looking at this great chart from Doug Short via Jill Mislinski.
Doug has a special knack for pulling together all the relevant information. His charts save more than a thousand words! Read the entire post for several more charts providing long-term perspective, including the size and frequency of drawdowns.

The Silver Bullet

As I indicated recently I am moving the Silver Bullet award to a standalone feature, rather than an item in WTWA. I hope that readers and past winners, listed here, will help me in giving special recognition to those who help to keep data honest. As always, nominations are welcome!

The News

Each week I break down events into good and bad. For our purposes, “good” has two components. The news must be market friendly and better than expectations. I avoid using my personal preferences in evaluating news – and you should, too!
The economic news last week was generally positive.
The Good
  • North Korea backed off from a threatened missile launch toward Guam. There were some signs that diplomacy might prevail over military escalation.
  • Retail sales increased 0.5%, handily beating expectations of 0.3%. New Deal Democrat notes both the strength and upward revisions to prior numbers. Steven Hansen (GEI) confirms the interpretation with his year-over-year, rolling average approach. E-commerce sales continued to lead, growing 16.2% year-over-year. Horan Capital Advisors has more detail, including this chart.
  • NAHB housing market index moved much higher (68 v last month’s 64) and handily beat expectations of 65.
  • Leading indicators, jobless claims and industrial production matched the positive expectations.
The Bad
  • Rail traffic remains in contraction when analyzed without coal and grain. Steven Hansen (GEI).
  • Building permits and housing starts both declined and missed expectations. Calculated Risk notes that multi-family is volatile, mostly moving sideways, but down 35% year-over-year. Single-family starts are up 10.9% year-over-year.
The Ugly
The cholera outbreak in Yemen has now spread to 500,000 people in the last four months. Stat provides perspective and describes the struggle to fight this disease. 30,000 health care workers have not been paid in more than a year.

Noteworthy

Better Congressional procedures would encourage more efficient attention to legislation. The Bipartisan Policy Center does a six-month review of the 115thCongress. Questions like number of days worked, use of committees, and delays are part of this analysis.
The Week Ahead
We would all like to know the direction of the market in advance. Good luck with that! Second best is planning what to look for and how to react.
The Calendar
It is a modest economic calendar, with continuing summer vacations for many. Will there finally be a quiet week? I am especially interested in New Home Sales.
The Kansas City Fed’s annual Jackson Hole Economic Policy Symposium begins on Friday. Chair Yellen is the headline speaker, with the topic of “financial stability.” ECB President Mario Draghi will attend, but is not scheduled to speak.
Briefing.com has a good U.S. economic calendar for the week (and many other good features which I monitor each day). Here are the main U.S. releases.
Next Week’s Theme
Once again, the idea of a slow summer week, with Presidential and Congressional vacations, was completely wrong! The Charlottesville story is vitally important, but not so much for financial markets. The Administration’s controversial handling of the issue pushed it front and center. We can expect a focus on a specific threat:
Will the Trump team turmoil threaten the legislative agenda?
Last week’s decline proved to be a dip. Will this week be the same? Opinions differ sharply.
I forced myself to listen to pundit speculation, just so I could summarize the wild range. Please remember that our interest is not about the political and personal ramifications of events. My concern here is what this means for financial markets and our investments. Here is the speculation:
  • The Trump Administration has been crippled, preventing any progress on his important agenda.
  • The loss of key advisors will leave the Administration without needed expertise. (This was often cited as the proximate cause of mid-week market weakness).
  • The Bannon departure improved the chances for cooperation with Congress. (This was cited as the cause of Friday’s short-lived rebound. It was even cheered on the NYSE floor by the largely Republican traders).
  • The Bannon departure would weaken the Administration because he would now attack from outside. He could also pressure members of Congress who could face primary challenges from the right.
  • And finally, anyone who has been calling for a correction will inform you that “the time is now.” The claim is that a correction-ready market simply needs an excuse.
Last week I cited some sound, dependable sources about Korea – material worth reading. This week you will be bombarded with viewpoints whether you want to be or not. Play golf. Go fishing. See a ball game. Spend time with your family. Most of the commentary serves a specific political or market viewpoint.
As usual, I’ll have more in my Final Thought, emphasizing the key issues we should be watching.
Quant Corner
We follow some regular featured sources and the best other quant news from the week.
Risk Analysis
I have a rule for my investment clients. Think first about your risk. Only then should you consider possible rewards. I monitor many quantitative reports and highlight the best methods in this weekly update.
The Indicator Snapshot
The Featured Sources:
Bob Dieli: Business cycle analysis via the “C Score.
RecessionAlert: Strong quantitative indicators for both economic and market analysis.
Brian Gilmartin: All things earnings, for the overall market as well as many individual companies.
Doug Short: Regular updating of an array of indicators. Great charts and analysis.
Georg Vrba: Business cycle indicator and market timing tools. It is a good time to show the chart with the business cycle indicator.
James Picerno’s business cycle work also has a positive, data-driven conclusion.
The US economy continued to exhibit a moderate growth bias through July. Although the monetary backdrop still presents a mild headwind, the majority of key indicators published to date suggest that recession risk remains low.

Near-term projections of the macro trend also point to a low probability that the economy will suffer a dramatic deterioration. The eight-year-old US expansion, in short, still looks resilient at the moment.
Insight for Traders
We have not quit our discussion of trading ideas. The weekly Stock Exchange column is bigger and better than ever. We combine links to trading articles, topical themes, and ideas from our trading models. This week’s post, Is the Bull Market Slowing?, showed how traders are coping. Blue Harbinger has taken the lead role on this post, using information from me and from the models. He is doing a great job.
Insight for Investors
Investors should have a long-term horizon. They can often exploit trading volatility!
Best of the Week
If I had to pick a single most important source for investors to read this week it would be the clear and calming words of the Fear and Greed Trader. He writes as follows:
With the major indices at or near all-time highs, low volatility, and everyone clamoring for a correction, the discussion has been ramped up about bubbles, stock market tops, etc. We've heard quite a bit of chatter about the bull market’s end being near. It’s too old and tired, its time has come. These calls have come and gone as the bull market has aged over the years.
The rhetoric gets ramped up the higher stock prices go by those that perceive something has to give, be it sooner or later. The perceived bubble has to burst. Therefore, the incessant "There is a stock market crash coming soon" comments portray a perception that is dealing with imagination and speculation rather than facts.
His work, as usual, has plenty of sound data, charts, and good sources. Like me, he is willing to change viewpoints with the evidence, but not when the economy is solid (Atlanta GDP now at 3.8%) and recession chances small.
As I note in today’s Final Thought, it is difficult to reach the right conclusion if you start with a misperception of the facts!
Stock Ideas
Chuck Carnevale has a fascinating post on Warren Buffett’s decision to sell General Electric (GE) and buy Synchrony Financial (SYF). Chuck has done prior research on GE under the tenure of the two most-recent CEO’s. He provides some insight into why a value investor might well prefer the spinoff financial company.
John Rhodes reaches a similar conclusion, shifting some assets to Synchrony from American Express (AXP). Besides its status as the largest private-label card, he cites some of their business relationships.
Steve Castellano likes Dollar General (DG), which he sees as competing successfully against Wal-Mart (WMT).
Peter F. Way uses his market maker hedging approach to compare CVS and Walgreens. While both have reasonable levels of safety, his method highlights some retail choices that investors might prefer.
Dividends and Yield
David Fish highlights seven champions expected to boost dividends before the end of October. His post describes the amazing record of these companies and adds some valuation analysis.
Mark Hines likes Omega Health Care (OHI), making it his “idea of the month.”
Personal Finance
Seeking Alpha Senior Editor Gil Weinreich has an interesting topic every day. His own commentary adds insight and ties together key current articles. My favorite this week was Success Through Booms, Crashes, Inflation And Recession. (Close runner-up is about not botching your retirement!) As is customary in this daily column there is something good for advisors as well as individual investors. He also recommended Cullen Roche’s excellent explanation of current household debt data. This has a lot of information that most neglect along with some excellent charts.
Strategy and Outlook
Ben Carlson has seven strategies for investing at market tops, although that is not what he is predicting. This inspired me to generalize my own thoughts on rebalancing portfolios as conditions change.
Eddy Elfenbein notes the increase in volatility while emphasizing the quiet background – his usual calm and wise advice.
Horan Capital Advisors explains why the economy still has upside via an increase in labor force participation.
Ralph Vince remains bullish.
Watch out for….
…Your bond fund? Morningstar warns that it might be riskier than it looks. The analysis describes risk changes, using the Sharpe ratio, in recent years versus data starting in 2002. Very interesting.
Final Thoughts
Where you end up depends a lot on where you start.
If you think that the post-election rally is all about Trump, you see the market as imperiled by changes in his team. If you see stocks as dependent upon the Administration’s ability to steer a specific agenda through Congress, you watch each twist and turn with bated breath.
If, like me, you had the following view:
  1. Expecting a post-election rally whomever won, just because uncertainty would be removed. (It is what I said at the time).
  2. Analyzing the Trump agenda in terms of the potential for compromise. This has also been consistent and accurate.
  3. Evaluating the market on important factors that have been correct since the move from Dow 10K to Dow 20K.
    1. Valuation compared to alternatives – positive
    2. Valuation compared to inflation – positive
    3. Risk of recession – extremely low
    4. Financial stress – extremely low
    5. Market skepticism – extremely high
  4. Viewing some issues (debt ceiling change) as a threat and others (tax reform) as significant upside. The balances are positive.
With that background, the pending questions and conclusions gain some clarity.
The punditry on Friday was comical. CNBC ran multiple charts explaining each 50-basis point move in the market with some “breaking news.” The market was soft. Bannon was going to be fired, so markets rallied. Bannon might go on the attack against Trump. Markets declined.
Those trading on a time frame of a few minutes had to react to such action, but for the average investor it is complete nonsense. What should you be watching?
Most important is any sign of bipartisan compromise. This is the key indicator of the prospects for a market-friendly agenda.
Another possibility is a reduced possibility of a trade war. (Bannon was one of the most vigorous on trade issues). A tax cut might even be made retroactive (The Hill).
[Some readers might enjoy my recent short paper, Getting Back in the Market. This has more specific suggestions about attractive stock sectors and good tactics. The Top Twelve Investor Pitfalls will help with your plan. Understanding Risk might also be of interest. All are free at your request from info at newarc dot com].
What worries me…
  • Perceptions about the upcoming debt limit issue. No signs of progress so far, and it will be hitting the headlines.
  • Similarly, perceptions about leadership. If enough people conclude that there is a problem, there will be a problem.
…and what doesn’t
  • The Fed. That includes both rate increases at a reasonable pace and the planned balance sheet reduction. Expect these worries to be heating up this week, before the annual Jackson Hole conclave.
  • Recession worries. Nothing peps up a dull story like a headline which includes “Next Recession is Looming.”
Disclosure: I am/we are long OHI, CVS.
By Jeff Miller

Monday, May 11, 2015

Week ahead: 9 IPOs planned for the week of May 11

Image result for IPO's

Nine IPOs are scheduled to raise $1.4 billion this week . 
The IPO market could see the year's largest company and the year's largest biotech by market cap begin trading in the US. Two yield plays account for two-thirds of expected proceeds. Six of the nine are development-stage health care and genetics companies, four of which had delayed their IPOs.

Last week, just 8 of 14 IPOs managed to price and just one gained more than 10% on its first day. Expect similar pushback this week. Voters in our IPO Poll are not enthusiastic.

Incentives for sale: EQT GP set to be year's largest company to IPO
EQT GP Holdings LP (EQGP) offers investors a levered play on natural gas pipeline MLP EQT Midstream's ( EQM )

 rising distributions through the GP's equity interests and incentive distribution rights. The underlying MLP has gained 300% since its June 2012 IPO. Signaling investor demand, Tallgrass Energy GP LP (TEGP) became the year's largest IPO by deal size and market cap after it priced above the range, then traded up 9%. EQT GP will have a relatively low float; the offered shares represent just 7.5% of its market cap.

Fortress Transportation and Infrastructure Investors LLC (FTAI) is set to raise $400 million. Formed by private equity firm Fortress Investment Group ( FIG )

 FTAI owns a portfolio of aviation, rail and marine transportation and logistics assets. The company pitches itself as being able to respond to market conditions by shifting resources while closing on acquisitions at attractive prices. It offers an initial yield of more than 6%.

Year's largest biotech to offer shares in the US
Galapagos (GLPG), which trades in Europe under the ticker GLPG, plans to raise about $200 million by listing in the US. Primary shareholder Johnson & Johnson ( JNJ )  and AbbVie ( ABBV )

 plan to invest $55 million on the offering of the inflammatory disease biotech. Its stock has gained over 130% year-to-date and is up 50% since it first filed to list in the US. Its market cap of $1.6 billion surpasses March IPO Cellectis (CLLS; -24%), which was also listed in Europe and traded up significantly prior to the US offering.

Fenix Parts (FENX), a recently formed rollup of auto parts manufacturers, plans to raise $110 million, representing 66% of its market cap. Much larger peer LKQ ( LKQ )

 sold off in late February but the stock recovered two weeks ago.

Four delayed biotechs - topical Botox, weight loss pill, gene therapy, dog diarrhea
Biotechs without big-name backers have had difficulty getting done as investor sentiment for the sector cools. Three biotechs that had originally been set to price last week will make a second attempt this week, though none have chosen a date. Of note, last week's two worst per formers, OpGen (OPGN) and CoLucid Pharmaceuticals (CLCD), had originally been on the calendar for the prior week and priced well below the range.

Weight loss pill maker Gelesis (GLSS) plans to raise $52 million; insiders intend to invest up to 34% of the deal. Led by former Introgen executives, MultiVir (MVIR) is developing gene therapies it acquired from now-bankrupt Introgen; its backer plans to buy up to 33% of the proposed $60 million deal. Topical botulinum toxin maker Anterios (ANTE), which did not disclose insider buying, targets a large but competitive market.
Jaguar Animal Health (JAGX) originally planned to raise $40 million at a 34% higher valuation in November 2014, but the pet diarrhea biotech dropped out. It could be bookrunner Aegis Capital's first IPO of 2015.


Renaissance Capital's IPO Calendar - Week of5/11/2015
Issuer
Business
Symbol
Exchange
Deal Size
$mil
Price Range
Shares Filed
Lead Manager(s)
EQT GP Holdings LP 
Pittsburgh, PA
EQGP
NYSE
$450$21 - $24
20,000,000
Barclays
Goldman Sachs
Owns GP and LP interests in midstream energy MLP EQT Midstream Partners.
Fortress Transportation and Infrastructure Investors LLC 
New York, NY
FTAI
NYSE
$400$19 - $21
20,000,000
Citi
BofA Merrill Lynch
LLC formed by Fortress to own aviation, rail and marine transportation assets.
Galapagos 
Mechelen, Belgium
GLPG
NASDAQ
$200$42.43
4,720,000
Morgan Stanley
Credit Suisse
Belgian biotech developing new treatments for inflammatory diseases.
Fenix Parts 
Miami, FL
FENX
NASDAQ
$110$9 - $11
11,000,000
BMO Capital Markets
Stifel
Recently formed rollup of eight recycled auto parts providers.
Arcadia Biosciences 
Davis, CA
RKDA
NASDAQ
$100$13 - $15
7,150,000
Credit Suisse
J.P. Morgan
Developing a portfolio of crop productivity traits for genetically modified seeds.
MultiVir 
Houston, TX
MVIR
NASDAQ
$60$12 - $14
4,600,000
RBC Capital Markets
Biotech developing gene therapies for cancer.
Gelesis 
Boston, MA
GLSS
NASDAQ
$52$12 - $14
4,000,000
Piper Jaffray
Stifel
Developing a weight loss capsule for patients with obesity and type 2 diabetes.
Anterios 
New York, NY
ANTE
NASDAQ
$51$12 - $14
3,900,000
Stifel
RBC Capital Markets
Developing a topical formulation of botulinum toxin.
Jaguar Animal Health 
San Francisco, CA
JAGX
NASDAQ
$22$7
3,150,000
Aegis Capital
Developing an animal formulation of its parent's approved diarrhea treatment.

Find out why institutional investors rely on Renaissance Capital's Pre-IPO Research for these IPOs. 
Follow us on Twitter ( @IPOtweet ) for IPO news as it happens and register for our updates on the IPO market. 

IPO pipeline update: Fitbit files 
Fitbit (FIT) joined the IPO pipeline last week when it filed for an IPO that we estimate could raise $400 million or more. While the consumer sector has seen less activity this year, chicken wing restaurant chain Wingstop (WING) also filed to raise 86 million. Two technology IPOs - e-commerce platform Shopify (SHOP) and e-Chinese e-commerce outsourcer Baozun (BZUN) - joined the IPO calendar for next week while Evolent Health's (EVH) initial filing suggests that the tech sector may be picking up. TerraForm Global (TERG.RC) was last week's largest filer with a $700 million deal size; the SunEdison (SUNE) yieldco owns solar and wind power assets in emerging markets and follows the successful 2014 IPO of US-focused TerraForm Power (TERP). 

IPO market snapshot 
The Renaissance IPO Index, a market cap weighted basket of newly public companies that is designed to represent the US IPO market, has traded up 6% year-to-date, compared to 3% for the S&P 500. Renaissance Capital's IPO ETF (IPO) tracks the index, and top ETF holdings include Alibaba (BABA), Twitter ( TWTR )

 Hilton (HLT), Ally Financial (ALLY) and Voya Financial (VOYA). To find out if this is the best ETF for you, visit our IPO investing page.
The article Week ahead: 9 IPOs planned for the week of May 11 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com. 

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.


By 
Source: http://www.nasdaq.com/article/week-ahead-9-ipos-planned-for-the-week-of-may-11-cm475110